We provide evidence that blocking CSF1R ameliorates the clinical course of ALS disease by reducing both the invasion of macrophages into peripheral nerves at pre-symptomatic stages of the disease, and by impeding microglia proliferation at late stages of the pathology. This evidence concerns the gene CSF1R and amyotrophic lateral sclerosis.